J O’Byrne

677 total citations
8 papers, 528 citations indexed

About

J O’Byrne is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, J O’Byrne has authored 8 papers receiving a total of 528 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Hematology, 2 papers in Oncology and 2 papers in Genetics. Recurrent topics in J O’Byrne's work include Platelet Disorders and Treatments (3 papers), Erythropoietin and Anemia Treatment (2 papers) and Neutropenia and Cancer Infections (2 papers). J O’Byrne is often cited by papers focused on Platelet Disorders and Treatments (3 papers), Erythropoietin and Anemia Treatment (2 papers) and Neutropenia and Cancer Infections (2 papers). J O’Byrne collaborates with scholars based in Australia, United States and India. J O’Byrne's co-authors include John E.J. Rasko, Jonathan Cebon, Brian M. Cohen, John A. Glaspy, Lee S. Schwartzberg, Glen R. Justice, Alan Colowick, J. Keßler, Russell L. Basser and C. Glenn Begley and has published in prestigious journals such as Blood, British Journal of Cancer and European Journal of Cancer.

In The Last Decade

J O’Byrne

8 papers receiving 499 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J O’Byrne Australia	6	471	102	81	77	60	8	528
R Cimino Italy	10	424 0.9×	100 1.0×	200 2.5×	46 0.6×	23 0.4×	22	531
Vittorio Fregoni Italy	11	173 0.4×	157 1.5×	103 1.3×	12 0.2×	52 0.9×	23	383
Clemens Leitgeb Austria	8	548 1.2×	208 2.0×	178 2.2×	68 0.9×	25 0.4×	13	639
T. Littlewood United Kingdom	4	179 0.4×	106 1.0×	85 1.0×	34 0.4×	34 0.6×	11	306
GR Morgenstern United Kingdom	9	327 0.7×	185 1.8×	60 0.7×	80 1.0×	21 0.3×	10	441
Dragica Tomin Serbia	12	353 0.7×	64 0.6×	114 1.4×	40 0.5×	32 0.5×	36	434
Gholamreza Toogeh Iran	10	226 0.5×	14 0.1×	92 1.1×	15 0.2×	52 0.9×	37	353
S. Luzi Fedeli Italy	6	176 0.4×	123 1.2×	38 0.5×	37 0.5×	63 1.1×	11	311
Özden Vural Türkiye	11	110 0.2×	63 0.6×	46 0.6×	4 0.1×	43 0.7×	20	314
Marshall Mazepa United States	11	296 0.6×	44 0.4×	86 1.1×	51 0.7×	20 0.3×	33	449

Countries citing papers authored by J O’Byrne

Since Specialization

Citations

This map shows the geographic impact of J O’Byrne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J O’Byrne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J O’Byrne more than expected).

Fields of papers citing papers by J O’Byrne

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J O’Byrne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J O’Byrne. The network helps show where J O’Byrne may publish in the future.

Co-authorship network of co-authors of J O’Byrne

This figure shows the co-authorship network connecting the top 25 collaborators of J O’Byrne. A scholar is included among the top collaborators of J O’Byrne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J O’Byrne. J O’Byrne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Cousins, Gráinne, et al.. (2011). A review of adverse event reporting in Irish surgical specialties. Clinical Risk. 17(2). 43–49. 3 indexed citations

2.

Glaspy, John A., Glen R. Justice, J. Keßler, et al.. (2002). Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. British Journal of Cancer. 87(3). 268–276. 138 indexed citations

3.

Glaspy, John A., Glen R. Justice, J. Keßler, et al.. (2001). A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. British Journal of Cancer. 84(s1). 17–23. 62 indexed citations

4.

Glaspy, John A., Glen R. Justice, J. Keßler, et al.. (2001). Randomized, active-controlled, phase , dose-comparison study of NESP administered weekly or every 2 weeks in patients with solid tumors. European Journal of Cancer. 37. S353–S353. 17 indexed citations

5.

Toner, Guy C., Michael D. Green, James F. Bishop, et al.. (1998). Dose Escalation Study of Carboplatin and Cyclophosphamide With Filgrastim Support. American Journal of Clinical Oncology. 21(3). 263–269. 2 indexed citations

6.

Rasko, John E.J., Russell L. Basser, Cindy J. O’Malley, et al.. (1997). Multilineage mobilization of peripheral blood progenitor cells in humans following administration of PEG‐rHuMGDF. British Journal of Haematology. 97(4). 871–880. 51 indexed citations

7.

Basser, Russell L., John E.J. Rasko, Kerrie Clarke, et al.. (1997). Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer.. Blood. 89(9). 3118–28. 149 indexed citations

8.

O’Malley, Cindy J., John E.J. Rasko, Jonathan Cebon, et al.. (1996). Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation. Blood. 88(9). 3288–3298. 106 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact